Pfizer bags an FDA OK for PARP player talazoparib — now the hard part begins
Pfizer has picked up an approval for talazoparib, its PARP inhibitor for a genetically defined line of breast cancer. And now the pharma player can …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
